Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease.

Gut·2025
Same author

The adult large bowel: describing environment morphology for effective biomedical device development.

Progress in biomedical engineering (Bristol, England)·2024
Same author

Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease.

BMJ open gastroenterology·2024
Same author

Multi-task learning with cross-task consistency for improved depth estimation in colonoscopy.

Medical image analysis·2024
Same author

Magnetic flexible endoscope: a novel platform for diagnostic and therapeutic colonoscopy.

iGIE : innovation, investigation and insights·2024
Same author

Inflammatory Bowel Disease-Associated Colorectal Cancer Epidemiology and Outcomes: An English Population-Based Study.

The American journal of gastroenterology·2022

Related Experiment Video

Updated: Jun 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Clostridium difficile and inflammatory bowel disease: implications for current clinical practice.

Venkataraman Subramanian1

  • 1Nottingham Digestive Diseases Centre and Biomedical Research Unit, Nottingham University Hospital (QMC campus) Nottingham NG7 2UH UK.

F1000 Medicine Reports
|October 16, 2010
PubMed
Summary

Clostridium difficile infection mimics inflammatory bowel disease (IBD) flares and is rising. Early diagnosis and oral vancomycin may reduce colectomy rates in IBD patients.

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Related Experiment Videos

Last Updated: Jun 8, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Epidemiology

Background:

  • Clostridium difficile infection (CDI) is increasingly prevalent in Europe and North America, with emerging hypervirulent strains.
  • CDI can induce or mimic inflammatory bowel disease (IBD) flares, complicating diagnosis and management.
  • IBD patients may contract CDI without prior antibiotic use or hospitalization, and often lack typical pseudomembranes.

Purpose of the Study:

  • To emphasize the importance of including CDI in the differential diagnosis for IBD patients with refractory symptoms.
  • To highlight the rising incidence and severity of CDI, particularly in IBD populations.
  • To review diagnostic approaches and treatment strategies for CDI in IBD.

Main Methods:

  • Review of current epidemiologic data on CDI incidence and strain emergence.
  • Discussion of diagnostic methods, including toxin testing and serial stool samples.
  • Analysis of treatment outcomes, focusing on oral vancomycin and colectomy rates.

Main Results:

  • CDI is associated with prolonged hospital stays, increased mortality, and higher complication rates, including colectomy, in IBD patients.
  • Oral vancomycin may be associated with reduced colectomy rates in this patient group.
  • Standard diagnostic criteria may not apply to CDI in IBD patients.

Conclusions:

  • CDI should be a primary consideration in IBD patients presenting with worsening symptoms.
  • Prompt diagnosis and appropriate treatment, potentially with oral vancomycin, are crucial for managing CDI in IBD.
  • Preventive measures, including antibiotic stewardship and enhanced hygiene, are vital to curb the rising incidence of CDI.